Over the past decade, BioCanRx has done something most national science networks only describe in strategy documents: it has moved a made-in-Canada cancer immunotherapy from academic laboratory to patient bedside at scale. More than ninety patients treated through CLIC-01. CLIC-02 actively recruiting across seven clinical sites, including pediatric centres. CanPRIME 2.0 live at six regional training nodes. A parallel health technology assessment underway to build the cost-effectiveness case before provincial budgets are set. The analytical and scientific work is substantial and ongoing.
The work that remains is of a different kind. The challenges that will determine whether Canada’s made-in-Canada immunotherapy model reaches patients at scale are not primarily scientific. They are coordination problems — situations where the answer is largely knowable, the evidence is accumulating, and the frameworks are drafted, but where the constraint owners have never been in the same room with binding authority to resolve the trade-offs between them. Several triggers converge in 2026 to make these challenges urgent: CLIC-02 operating at full multi-site tempo, CanPRIME 2.0 launched nationally without a recognized common standard, a non-binding regulatory framework for point-of-care manufacturing, and a federal funding adjustment that is legally deferred to 2028–29 but operationally live now.
This article traces that pattern across six challenges in BioCanRx’s current portfolio, then works through in detail how a structured, decision-forcing process would play out against two of them: the cross-site manufacturing governance challenge posed by CLIC-02, and the national curriculum standardization challenge posed by CanPRIME 2.0.
Several triggers converge in 2026 to make BioCanRx’s coordination challenges urgent rather than chronic. CLIC-02 (NCT06208735) is now operating at full multi-site tempo, requiring harmonized manufacturing across nodes that each answer to their own hospital governance.2 CanPRIME 2.0 has launched nationally, but a curriculum that must be simultaneously accredited by six university–college partnerships across six provinces is not yet a standard — it is a collection of parallel programs.3 Health Canada’s Advanced Therapeutic Products framework, intended to provide regulatory certainty for point-of-care manufacturing, remains non-binding after stakeholder consultations produced agreement in principle but not in statute.5 Canada’s Drug Agency flagged adoptive cell therapies on its April 2026 Watch List as a high-cost emerging category requiring advance payer preparation.6 And a federal funding adjustment to the Strategic Science Fund, deferred to 2028–29, is already forcing programmatic decisions that cannot wait for the fiscal year in which the cut actually lands.7 The SSF renewal competition is expected to open in the 2026–27 window — with the evaluation period overlapping exactly with the years in which the network’s output must speak for itself.
Each of these developments shares a structural signature: multiple parties who each control a necessary piece of the solution, high stakes for getting the alignment wrong, a clock that is already running, and analysis that is ahead of the coordination it requires. BioCanRx is not unusual in facing this condition. National networks operating at the boundary of what existing institutions were built to handle routinely arrive at this moment. If anything, the calibre of BioCanRx’s scientific and policy output — the CLIC platform, the IOG governance benchmarking report, the parallel HTA investment — makes the distinction between what is known and what has been resolved unusually visible.
The developments of the past year, read together, form a recognizable shape. In each challenge, BioCanRx holds part of the answer, several other parties hold the rest, and there is a clock running. The tiles below name each challenge, the structural condition that keeps it open, and the trigger that makes it live now.
The CLIC-02 trial is the first in the CLIC platform to run simultaneously across multiple hospital-based GMP manufacturing nodes, targeting the CD22 antigen for patients — including children — who have relapsed after CD19-directed therapy.2 Each site manufactures its own product against a six-week vein-to-vein target that is not a preference but a clinical necessity. The 2025 technology transfer of CLIC-1901 protocols to the OHRI Biotherapeutics Manufacturing Centre demonstrated that decentralized production works.8 The question now is whether it works equivalently — across seven nodes, under different hospital quality systems, with no pan-Canadian authority to mandate harmonization. Every constraint owner can agree that common standards are desirable, and none can impose them.
Canada has invested heavily in physical biomanufacturing infrastructure. The bottleneck is the people qualified to operate it. BioCanRx and Mitacs responded with CanPRIME 2.0, a $2.22 million co-investment that launched six regional training nodes in 2025–26.3 The original Ottawa pilot achieved a hundred-percent employment rate for graduates.9 Scaling that result nationally requires a competency standard that is portable across provinces, recognized by employers in different sectors, and updatable as manufacturing technology evolves. Today, CanPRIME 2.0 is six parallel programs. The distance between that and a national standard runs through college accreditation boards, university curriculum committees, provincial ministries of education, and industry hiring managers — parties whose governance structures do not naturally intersect.
Health Canada’s Advanced Therapeutic Products framework was designed to give point-of-care manufacturers a regulatory pathway that fits how these therapies are actually produced.5 After extensive stakeholder consultations, the department shifted from formal draft guidance to a non-binding InfoHub. The United Kingdom enacted binding MHRA point-of-care manufacturing regulations in 2025.10 Canada’s international research partners and potential commercial co-developers are operating in one jurisdiction with statutory clarity and one without. The April 2026 CDA-AMC Watch List noted explicitly that clearer ATP guidance “could help support industry planning.”6 The cost of the current ambiguity is paid in delayed facility investment, conservative enrollment decisions, and a competitive disadvantage in attracting the private capital needed to advance CLIC therapies beyond Phase I.
Dr. Kednapa Thavorn’s health economics study is building the cost-utility and budget-impact models that will make the case for provincial reimbursement of decentralized CAR-T therapy.11 That study runs to late 2027. Provinces set their 2028 budgets before that data is complete. Commercial CAR-T therapies carry list prices above $400,000 per infusion; recent pCPA negotiations for Carvykti stalled on cost-effectiveness grounds. BioCanRx’s decentralized model removes the commercial markup and the cross-border logistics cost — but that argument needs evidence to be procurement policy, and the thirteen provincial drug plans each make independent decisions on different timelines. Agreement among payers on what evidence is sufficient, and what a managed-access pathway might look like, is not a calculation any individual organization can perform alone.
In March 2026, ISED re-opened signed Strategic Science Fund contribution agreements and reduced the fund by $20 million across seventeen of nineteen recipient organizations.7 BioCanRx’s reduction is deferred to the 2028–29 fiscal year — a design choice that limits immediate disruption to active payrolls and enrolled patients. But parliamentary appropriation clauses make that future cut a present constraint: organizations managing multi-year clinical trials and training commitments cannot responsibly enroll patients, hire staff, or expand nodes against a funding envelope they cannot guarantee.12 Every trade-off the cut requires — which programs to protect, which sites to slow, how to preserve the renewal narrative for the 2029–34 SSF competition — involves stakeholders who each answer to a different authority and absorb the consequences differently. That is not a financial problem with a spreadsheet solution.
A December 2025 benchmarking report by the Institute on Governance, commissioned by BioCanRx, documented a structural pattern practitioners in the sector know well: Canada’s advanced therapies fall between mandates — deemed too applied for Tri-Council foundational funding, too risky for private capital markets.13 The result is a predictable out-licensing cycle. Turnstone Biologics — an Ottawa-based company supported by the BioCanRx ecosystem — signed a licensing agreement with AbbVie granting rights to up to three Maraba-virus immunotherapy programs on undisclosed terms.14 Virica Biotech, another BioCanRx-supported spinout, made a different choice: retaining manufacturing IP in Canada and building against domestic network partners first.15 The difference between those trajectories is not accidental. It reflects the presence or absence of coordinated public-private structures that allow domestic capital and clinical infrastructure to hold assets through later development stages.
Each of these challenges carries a recognizable structural signature: multiple parties who each control a necessary piece of the solution, high stakes for getting the alignment wrong, a clock that is already running, and analysis that is ahead of the coordination it requires. The question in every case is the same — not what should happen, but how to get the people who control what needs to happen into a process that forces the trade-offs into the open.
The convenings BioCanRx already runs — the Summit4CI, the Learning Institute, the network’s ongoing stakeholder engagements — do what large-format convenings are built to do. They confirm where stakeholders agree, build high-level alignment on causes, and create the conditions under which more specific work becomes possible. The March 2026 Summit4CI in Vancouver brought together approximately 350 participants across science, health economics, industry, and policy.16 That concentration of expertise, in one place at one time, is genuinely hard to assemble. These gatherings produce real value.
The format has a boundary that is not a shortcoming of the organizer — it is a feature of the format itself, and it holds across every complex national network. Large convenings are not built to force trade-offs. The people who must implement a decision — the hospital QA officer who will sign off on a revised SOP, the college curriculum committee chair who will approve a new competency standard, the provincial payer who will set a reimbursement threshold — are rarely present with the authority to commit. Agreement reached at a higher altitude tends to stay general, because the people whose sign-off is required are not in the room.
There is a useful self-test for any complex coordination challenge: if the same issue appears on successive agendas — same stakeholders, same trade-offs unresolved, same acknowledgment that alignment is needed — that is the signal that a different tool would help resolve it. Not replace the convening. Work alongside it, and take the next step the convening has prepared but cannot complete: getting the constraint owners into a room where the trade-offs must be resolved, not deferred.
That room is a different instrument. Its value lies not in the expertise it assembles — BioCanRx’s network has no shortage of that — but in the process it runs: structured to surface what each party actually controls, generate options that cross the boundaries no single institution can see past, and produce a plan that every constraint owner has co-authored and is prepared to carry back into their own organization.
The following two examples walk the Analyze → Diverge → Converge sequence through the CLIC-02 manufacturing challenge and the CanPRIME curriculum standardization challenge. The intent is not to prescribe specific outcomes — those belong to the people in the room — but to show what the process surfaces at each stage that sequential consultation does not.
The Analyze stage is not a literature review or a gap assessment prepared in advance and presented to participants. It is a structured process in which the constraint owners themselves — the OHRI-BMC manufacturing team, the BC Cancer Genome Sciences Centre, the QA officers at each clinical site, Health Canada representatives, the clinical investigators — surface what each party actually controls and where the dependencies run.
In the CLIC-02 manufacturing system, that map has a specific shape. Plasmids originate at the BC Cancer Genome Sciences Centre. Lentiviral vectors are produced at the OHRI-BMC and distributed to all nodes. Each site then performs final cell engineering using its own staff, its own quality management system, and its own hospital governance — which means the same protocol, applied by different teams in different institutions, must produce biologically equivalent product against a six-week clinical deadline.
What Analyze surfaces is not the existence of that architecture — everyone in the network knows the architecture. It surfaces where the actual control points lie. Which SOP parameters are non-negotiable on safety grounds, and which represent institutional preference? What is the realistic throughput ceiling at OHRI-BMC under current resourcing? What does each hospital QA officer need from a cross-site standard before their governance body will adopt it? What regulatory position has each site independently taken with Health Canada, and where do those positions conflict? Participants often arrive believing the problem is primarily technical; the Analyze stage typically reveals it is primarily jurisdictional.
Dimensions of this challenge:
| Dimension | What it governs | Why it cannot be solved in isolation |
|---|---|---|
| SOP harmonization | The specific manufacturing protocols each node follows — reagent lots, processing parameters, release criteria | Each hospital’s quality system has independent authority over its own SOPs; a standard imposed from outside requires voluntary adoption by every QA officer |
| Vector supply reliability | The lentiviral vectors produced at OHRI-BMC and distributed to all clinical sites | If the central supply node is under-resourced or disrupted, every downstream site is simultaneously affected — a risk multiplier unique to decentralized architecture |
| Site qualification criteria | The process and thresholds for onboarding new manufacturing nodes to the network | Health Canada, clinical investigators, and hospital administrators each apply different standards; a new site cannot proceed until all three are aligned |
| Real-time quality monitoring | Shared data systems for detecting manufacturing drift, batch failures, or process deviations across sites | No single institution owns the cross-site data; building a shared monitoring layer requires each hospital to share quality data it currently holds under its own governance |
| ATP regulatory alignment | How Health Canada’s Advanced Therapeutic Products framework applies to each node’s manufacturing authorization | The framework is currently non-binding; each site is independently navigating regulatory uncertainty without a coordinated position to present to the regulator |
| Failure-mode protocols | What happens when a manufacturing batch fails at a specific node — patient management, supply rerouting, regulatory notification | Patient safety obligations are site-specific; a network-level protocol requires every node to pre-commit to procedures that may conflict with local hospital policy |
The Diverge stage uses structured brainstorming across cognitively diverse teams — each team deliberately mixing manufacturing specialists, QA officers, Health Canada representatives, clinical investigators, and provincial agency staff who do not ordinarily share a design table. The task is to generate options for the manufacturing governance problem, not to evaluate them.
Working from the constraint map produced in Analyze, teams surface options that no single institution would generate alone. A shared SOP registry with a common floor and node-specific appendices, maintained by BioCanRx and adopted voluntarily by each site’s quality system. A centralized real-time batch-monitoring dashboard that each node feeds and that BioCanRx operates as network coordinator — providing early warning of manufacturing drift without requiring each hospital to share proprietary quality data bilaterally. A joint regulatory position, submitted to Health Canada as a consortium rather than as individual sites, proposing a specific transitional pathway for CLIC-02 under the ATP framework. A defined failure-mode protocol specifying how patient management, supply rerouting, and regulatory notification proceed when a batch fails — agreed in advance rather than negotiated in crisis.
The Converge stage resolves the trade-offs. Which options are adopted, in what form, and by whom. This is where the process earns its value — not by producing a set of recommendations for leadership to consider later, but by requiring the constraint owners present to commit, in the room, to specific actions they will carry back into their own organizations.
For CLIC-02 manufacturing harmonization, Converge produces: a harmonized SOP framework with a named custodian at each node and a defined protocol for cross-site updates; a vector supply agreement between OHRI-BMC and each clinical site specifying production schedules, quality release criteria, and contingency arrangements; a joint Health Canada submission on the ATP transitional pathway, signed by all CLIC-02 investigators; and a network-level failure-mode protocol that every site’s quality management system has incorporated. The 30/60/90 plan specifies who does what and by when. The people who agreed to it are the people whose organizations must execute it.
The village that must be in the room:
| Stakeholder | Role in the problem | Why their absence stalls the solution |
|---|---|---|
| OHRI Biotherapeutics Manufacturing Centre (BMC) | Central vector manufacturing hub; technology transfer lead for all nodes | Without BMC’s active commitment to scale and schedule, every downstream site’s manufacturing timeline is undefined |
| BC Cancer Genome Sciences Centre | Produces clinical-grade plasmids — the genetic starting material for all CLIC-02 product | Plasmid quality and delivery timelines set the ceiling for the entire network’s throughput; no other Canadian supplier holds this capability |
| Hospital QA officers at each node | Hold authority over each site’s quality management system and manufacturing SOPs | No cross-site standard takes effect unless each QA officer’s governing body approves it — alignment requires their genuine co-ownership, not downstream notification |
| Health Canada (Biologics and Radiopharmaceuticals) | Authorizes manufacturing and clinical conduct at each site; ultimately responsible for the ATP framework | Without regulatory clarity on what “equivalent product” means across decentralized nodes, each site must independently seek authorization — a process that multiplies timelines and risk |
| Clinical site investigators (Dr. Kevin Hay, BC Cancer; Ottawa and Alberta leads) | Responsible for patient enrollment and clinical conduct at each site | Manufacturing decisions affect patient eligibility windows; investigators must co-own the vein-to-vein timeline commitments that manufacturing governance produces |
| Provincial cancer agencies (BC Cancer, Alberta Health Services, Ontario Health) | Fund and administer the hospital programs that house the manufacturing nodes | Capital investment in GMP infrastructure at each node requires provincial agency sign-off; without their commitment, site qualification stalls regardless of scientific readiness |
The CanPRIME 2.0 network has the right architecture on paper: a university–college partnership at each node, backed by access to a functioning GMP facility and a Mitacs co-funding structure that makes trainee stipends viable.3 What the Analyze stage surfaces is the gap between architecture and standard.
Curriculum approval at each node runs through independent institutional governance chains. A college in Victoria and a college in Ottawa apply different accreditation standards, have different relationships with their provincial ministries, and answer to different industry advisory structures. The university partner at each node manages its own credit-recognition policies. The GMP facilities that provide hands-on training access — hospital-based cleanrooms, OHRI-BMC, provincial cancer agency labs — schedule student rotations according to their own operational priorities, not a national training calendar.
The result is that a CanPRIME graduate from one node is not automatically recognized as equivalent to a graduate from another — not by employers, not by regulatory bodies, not by the accreditation systems of other provinces. Industry employers, who are the ultimate test of whether the program works, are not formally embedded in curriculum governance. They are consulted, sometimes, after the fact. What Analyze makes visible — and what bilateral meetings between BioCanRx and individual institutions do not — is the full map of where the standard breaks, and who controls each break point.
Dimensions of this challenge:
| Dimension | What it governs | Why it cannot be solved in isolation |
|---|---|---|
| Competency framework | The specific GMP skills, knowledge, and behaviours a CanPRIME graduate must demonstrate to be deployment-ready | Competency definitions must satisfy both college accreditation bodies and industry employers — parties with different definitions of “qualified” that have not been reconciled nationally |
| Facility access equity | Ensuring every training node provides equivalent hands-on time in a functioning GMP environment | GMP facilities are owned by hospitals or private operators with independent scheduling priorities; access commitments require bilateral agreements at each of six sites |
| Instructor alignment | Common pedagogical standards and technical knowledge across all node instructors | Each college and university has its own hiring and professional development governance; a national instructor standard requires voluntary adoption by institutions with no obligation to each other |
| Industry advisory governance | A formal mechanism for employers to update curriculum content as manufacturing technology and regulatory requirements evolve | Industry partners are the end-users of the workforce but hold no formal authority in academic curriculum governance; creating that mechanism requires restructuring relationships between sectors that currently operate sequentially |
| Accreditation reciprocity | Recognition of CanPRIME credentials by employers and regulatory bodies regardless of which node issued them | Credential recognition is governed by provincial bodies and individual employer hiring standards; national reciprocity requires simultaneous commitments from parties in different jurisdictions |
| Funding continuity beyond 2028 | Sustaining node operations if federal co-funding through Mitacs or BioCanRx changes after the SSF cliff | Each node’s sustainability depends on a different mix of federal, provincial, institutional, and industry support; a network-wide continuity plan requires all funders to commit in advance to their share |
The challenge with CanPRIME’s governance is precisely that no single party can impose a national standard. BioCanRx can set requirements for programs it funds — but it cannot compel accreditation reciprocity across provinces, and it cannot guarantee that employer hiring criteria will align with whatever standard it defines. Mitacs can require participating institutions to meet certain program conditions — but Mitacs is a co-funder, not an accreditation body.
Diverge generates options from teams that include college curriculum chairs, university registrars, industry HR leads from OmniaBio and Moderna Canada, a Health Canada GMP qualification specialist, and provincial ministry of education representatives — in the same working groups, at the same time. Options that emerge from this configuration include: a BioCanRx-administered national competency passport that follows the trainee rather than the institution, recognized by employers because the employers co-designed the standards; a tiered curriculum structure with a universally assessed core module and institution-specific advanced content, allowing provincial accreditation of the core without requiring full curriculum harmonization; a joint industry–BioCanRx advisory council with formal curriculum update rights, meeting on a defined annual cycle; and a Mitacs-anchored credential that attaches to the research internship framework and provides portability independent of which college or university housed the student.
The Converge stage produces an agreement that the participants — not BioCanRx on their behalf — have authored. The national CanPRIME competency framework, with specific assessed outcomes that every node’s program must demonstrate and that every employer on the advisory council has committed to recognize. A governance body with defined membership, an annual update cycle, and a documented change-management protocol. A Mitacs-anchored credential that gives graduates portable recognition independent of their training location. Accreditation language, ready for submission to each provincial ministry, that two or three provinces commit to advance within a defined window — creating a reciprocity precedent that the remaining provinces can join.
The 30/60/90 plan specifies which institutions submit accreditation proposals and when; the first annual industry advisory council meeting and its agenda; the first cohort of students who will graduate under the unified competency standard. The people who committed to these actions are the curriculum chairs, the industry HR leads, and the provincial representatives who were in the room — not delegates who must return to get sign-off from the people who were not.
The village that must be in the room:
| Stakeholder | Role in the problem | Why their absence stalls the solution |
|---|---|---|
| Mitacs | Co-funder of CanPRIME 2.0 ($2.22M joint investment); administers the research internship framework that makes trainee stipends viable | Without Mitacs’s continued participation, the financial model for student stipends at each node collapses — the program depends on its funding structure, not just BioCanRx’s |
| Regional college partners (six nodes) | Deliver the hands-on, applied GMP training component of the curriculum | College accreditation boards must approve any standardized curriculum; a national standard requires each college’s independent governance process — one hesitant institution creates a gap in the network |
| University partners (six nodes) | Provide the foundational science and regulatory knowledge component; house students during placements | Universities and colleges at the same node must agree on curriculum division, credit recognition, and scheduling — an alignment that currently runs through separate institutional governance chains |
| Industry employers (OmniaBio, Moderna Canada, hospital pharmacies, Virica Biotech) | The ultimate destination for CanPRIME graduates; define what “deployment-ready” means in practice | Without formal employer input into the competency framework, curricula drift from hiring reality; industry partners must have genuine update authority, not just advisory status |
| Provincial ministries of education | Govern college and university accreditation in each province; determine whether CanPRIME credentials are formally recognized | Accreditation reciprocity across provinces requires each ministry to act; no federal body can compel recognition — it must be negotiated province by province |
| Health Canada (GMP qualification standards) | Sets the regulatory definition of a qualified GMP operator — the external standard all CanPRIME training is designed to meet | If the regulatory standard evolves and the curriculum update mechanism is slow, graduates may be certified to an outdated standard; Health Canada’s participation in curriculum review closes this gap |
The process described here is not a replacement for the Summit4CI, the Learning Institute, or the ongoing stakeholder engagement that BioCanRx manages across its network. Those convenings create the conditions under which a more targeted process becomes possible — they build the relationships, establish the shared vocabulary, and surface the challenges clearly enough to know which ones have reached the stage where constraint owners need to be in the room together.
The recurrence test is a useful signal. If CLIC-02 manufacturing harmonization, CanPRIME curriculum standardization, and the ATP regulatory pathway appear on BioCanRx’s agenda this year and again next year — with the same parties, the same trade-offs deferred, the same acknowledgment that alignment is needed — that pattern is informative. It does not indicate that the work is being done wrong. It indicates that the format being used has reached its natural boundary and that a different tool is needed for the next step. If, on the other hand, these challenges are being resolved and replaced by new ones, the existing process is doing its job and no new tool is required.
The complement the moment calls for is a process that takes what the convening has built — the shared understanding of the problem, the assembled expertise, the accumulated goodwill — and converts it into binding commitments made by the people whose sign-off is actually required. That conversion is not a matter of more analysis or a better slide deck. It is a matter of getting the right people into a room structured to force the trade-offs that open questions represent.
BioCanRx has built something that takes years and sustained coordination to produce: a functioning national infrastructure for made-in-Canada cancer immunotherapy, with clinical proof across multiple patient cohorts, a training pipeline scaling to six cities, a cost-effectiveness argument under construction, and a scientific network that the rest of the world is watching as a model for decentralized cell therapy delivery. The science is ahead of most comparable national programs.
The question that 2026 poses is whether the coordination infrastructure keeps pace. Not eventually — before the 2028–29 funding decisions are made under conditions of fiscal constraint, before CLIC-02 patients complete trials into an undefined provincial access pathway, before CanPRIME graduates arrive at nodes that do not yet share a recognized standard. These are not hypothetical risks. They are the natural next consequences of scientific success at national scale in a system where the constraint owners have not yet been in the same room.
The system is catchable. The evidence is strong, the network is assembled, and the people who control the necessary pieces are known by name. The remaining work is to get them into a process that resolves what analysis alone has not.
Mark McCarvill is the founder of Mind Meeting Group, a Vancouver-based strategy and facilitation firm. He has led more than 100 strategic workshops across pharmaceutical, government, and not-for-profit sectors, working with seven of the global top-twelve pharmaceutical companies and facilitating the alignment of more than 3,000 leaders and stakeholders. Mind Meeting Group specializes in complex, multi-stakeholder challenges where the answer is knowable but not yet executable — and where the right process, not more analysis, is what converts strategy into committed action.